Kornimate/medical-research-clean huggingface dataset:
comparison of triamcinolone with pentoxifylline and vitamin- e efficacy in the treatment of stage 2 and 3 oral submucous fibrosis

Conditions: Triamcinolone; Pentoxifylline; Vitamin E; Oral Submucosa Fibrosis; Tumor

Summary: to compare the efficacy of triamcinolone with pentoxifylline and vitamin e in patients with stage two and three oral submucous fibrosis.

to compare the efficacy of triamcinolone with pentoxifylline and vitamin e in patients with stage two and three oral submucous fibrosis. it was a randomized control clinical trial to compare efficacy of injection steroids versus pentoxifylline and vitamin e in the treatment of stage 2 and 3 osf patient. total 40 patients who presented with signs and symptoms of osf were enrolled in our study that was evaluated over the period of (january 2020 to september 2021). parameters taken in the study were age and mouth opening. descriptive statistics and paired t-test were used for statistical analysis.

Eligibility criteria:
inclusion criteria: * patients with clinically diagnosed osmf who have not undergone any treatment of osmf in past * patients willing to quit their tobacco chewing habit, gutkha areca nut smoking * patients who are ready to attend regular follow-ups exclusion criteria: * patients who have undergone any treatment for osf in past * patients with any evidence of cardiac, gastrointestinal, kidney, metabolic disorders, pregnant and lactating women's * patients with any co-existing disorder of the orofacial region other than osf which may interfere with the study protocol
assessment of pain and treatment success after vpt versus rct in mature permanent mandibular molars with sip: a rct

Conditions: Symptomatic Irreversible Pulpitis

Summary: assessment of postoperative pain and treatment success after vital pulp therapy versus root canal treatment in mandibular molar with signs and symptoms of irreversible pulpitis. the null hypothesis, there is no difference will be observed in the pain level and treatment success between two treatments.

after proper clinical and radiographic examination. teeth will be anesthetized and isolated using a rubber dam. the operative field will be disinfected. total caries removal will be done from outside making margin caries free to inside. the new diamond bur will be used to remove the last layer and exposed the pulp tissue. exposed pulp will be inspected under a dental operating microscope and hemostasis will be obtained. the teeth will be randomized into 2 intervention groups (vpt or rct). treatment will be finalized, and teeth will be restored with resin-modified glass ionomer followed by composite resin at the same appointment. ibuprofen 400mg will be prescribed to the patient if needed. patients will be asked to record postoperative pain after treatment on the pain score sheet.

Eligibility criteria:
inclusion criteria: * systemically healthy patients. * patient's age range more than 15 years. * mature permanent mandibular molars with deep caries. * clinical diagnosis of symptomatic irreversible pulpitis. * teeth with no need for the post. * healthy periodontium and mobility within normal limits. * patients who can understand the pain scale and can sign the informed consent exclusion criteria: * teeth with a negative response to vitality testing. * teeth with furcal bone loss. * teeth with sinus tract * teeth with swelling. * teeth with a non-restorable crown. * teeth with immature roots. * teeth with no pulp exposure even after caries excavation. * history of analgesic intake in the previous week. * history of antibiotic intake in the previous month. * insufficient bleeding after pulp exposure suggestive of partial necrosis of the pulp. * inability to control bleeding within 10 min. * radiographic evidence of external or internal root resorption vertical root fracture, perforation, calcification.

Keywords: sip
using fluorine-18-labeled fluoro-misonidazole positron emission tomography to detect hypoxia in head and neck cancer patients

Conditions: Head and Neck Cancer

Summary: the main purpose of this study is to evaluate low oxygen areas called hypoxia within tumors. these low oxygen areas are thought to be the reason why tumors are more resistant to chemotherapy and radiation treatment. an imaging technique using a hypoxia tracer called fluoromisonidazole (fmiso) can detect low oxygen areas within a tumor. this imaging technique, called a pet scan, uses positively charged particles to detect slight changes in the body's biochemistry and metabolism. fmiso pet scans have been performed in patients with head and neck cancer and have shown the ability to detect low oxygen areas within tumors.


Eligibility criteria:
inclusion criteria for cohort 1 and cohort 2 : * histologically confirmed diagnosis of head and neck carcinoma (excluding nasopharynx, paranasal sinus, salivary, and thyroid malignancies)any unknown primary squamous cell carcinoma of head and neck with gross nodes is allowed (2002 ajcc) * 18 years of age or older * must not have received prior radiation therapy or chemotherapy for this diagnosis. patients who have had their primary site tumor removed by surgery but still present with grossly enlarged lymph nodes are eligible for this study. * karnofsky performance status ≥ 70. exclusion criteria for cohort 1 and cohort 2: * all nasopharyngeal, paranasal sinus, salivary cancer, and thyroid malignancies * prior chemotherapy or radiotherapy within the last three years * patients that underwent previous surgical resection for the same disease (except for biopsy or surgery removing primary site tumor but still present with grossly enlarged lymph nodes) * any prior radiotherapy to the head and neck region * pregnant (confirmed by serum b-hcg in women of reproductive age) or breast feeding subject exclusion criteria for optional contrast mris • subjects with a known contraindication to the standard mri contrast agent (gadavist, a gadolinium-based contrast agent) and/or a recent estimated glomerular filtration rate (egfr) of 30 or less will be excluded from all dce-mris, and will instead receive non-contrast mris at the dce-mri time points.

Keywords: head neck 04-070
peripheral physiological measures as determinants of pain risk

Conditions: Polyneuropathies; Peripheral Nerve Injuries; Peripheral Nervous System Diseases; Chemotherapy Effects; Neuralgia

Summary: this study evaluates peripheral nervous system function using multiple excitability measures (mem) to obtain "electrophysiological pain phenotypes"

using mem for peripheral sensory and motor axons we want to identify a set of excitability measures that: 1. correlate with parameters of clinical pain and of pain processing in existing pain patients (cross sectional study), with the aim to obtain an objective pain biomarker. 2. predict development of neuropathic pain in susceptible patients (longitudinal study). neuropathic pain predictor for patients: i. undergoing surgical procedures associated with a relatively high risk of developing neuropathic pain such as thoracotomy and hernia repair ii. planning to start chemotherapy with potentially neurotoxic agents such as vincristine

Eligibility criteria:
inclusion criteria: * chronic peripheral neuropathic pain * painless patient with risk to develop neuropathic pain (post-surgery, chemotherapy-induced) exclusion criteria: * minors

Keywords: neuropathic pain quantitative sensory testing multiple excitability measures threshold tracking
pco2 elso (extracorporeal life support organization)

Conditions: Respiratory Failure

Summary: investigation of the association between paco2 change after extra corporeal membrane oxygenation (ecmo) initiation and neurological outcome and mortality in neonates treated by ecmo for respiratory failure.

retrospective analysis of the elso database investigating the association between the change of pco2 value after ecmo start and the risk of acute neurological event under ecmo defined by the onset of cerebral bleeding and/or ischemic stroke and/or clinical or electrical seizure and/or brain death.

Eligibility criteria:
inclusion criteria : * support by ecmo for respiratory indication exclusion criteria : * none

Keywords: ecmo neonates
the gut microbiome and metabolomics in chronic lower extremities threatening ischemia

Conditions: Chronic Limb-threatening Ischemia; Microtia

Summary: intestinal floras and their metabolites are involved in progressing metabolic and cardiovascular diseases. however, currently, articles related to the relationship between intestinal floras and atherosclerosis mainly focus on coronary atherosclerotic disease (cad) population, or atherosclerosis model animals such as apoe-/-, ldlr-/- high-fat diet mice, and there are few studies on chronic limb-threatening ischemia (clti). clti and cad have a similar pathological basis of atherosclerosis. it is unclear whether intestinal flora plays an essential role in the occurrence and development of clti. this project aims to explore the relation between microorganisms, metabolites, and clti.

this project aims to study the intestinal flora and its metabolites in patients with clti, explore whether clti patients and cad patients have their own characteristic flora, analyze the microorganisms and metabolites markers of poor prognosis in patients with clti, and screen out the key differential bacteria and metabolites that inhibit the progress of clti, in order to provide new insights and research basis for the treatment of clti.

Eligibility criteria:
inclusion criteria: control group: sex - and age-matched healthy people (without history of atherosclerotic plaque, coronary heart disease or stroke). case group: resting pain for at least 2 weeks with at least one hemodynamic index: abi\<0.4,ap\<50mmhg, tp or tcpo2\<30mmhg. tissue defects (ulceration or gangrene) persisted for at least 2 weeks with at least one significant pad objective evidence: abi\<0.8, ap\<100mmhg, tp or tcpo2\<60mmhg. exclusion criteria: 1. patients with inflammatory bowel disease, autoimmune diseases, malignancies, infectious diseases, and severe liver and kidney dysfunction (cirrhosis, ckd stage 4 and 5). 2. patients with thromboembolic angiitis, arterial embolism, and takayasu. 3. patients who have used probiotics or antibiotics in the last 2 months. 4. after interventional surgery and amputation below the knee or above knee.
perineural platelet-rich plasma for diabetic neuropathy pain

Conditions: Diabetic Neuropathies; Chronic Pain

Summary: peripheral neuropathy is very common in diabetes mellitus (dm). till now there is no available effective therapy for this pathology. objective: to evaluate the clinical effect of perineural platelet-rich plasma (prp) injection as a treatment of diabetic peripheral neuropathy (dpn).

diabetic peripheral neuropathy (dpn) is a common complication of diabetes mellitus (dm). among several complications that contribute to reduce patient's quality of life and life expectancy diabetic neuropathy (dn) generalized or focal leads to an impaired life quality. the clinical symptoms of dpn range from pain and burning sensations, more at rest or at night; to hypoesthesia or paresthesia, and or numbness. different types of peripheral neuropathy are observed in diabetes, axonal or demyelination or both can be present, involves myelinated and un-myelinated, large and small fibers. nerve conduction studies can detect these changes. till now, there is no effective therapy for the treatment of dpn. since 1950 platelet-rich plasma (prp) has been used in dermatology and oral maxillofacial surgery, but its role as an effective alternative treatment in many other clinical applications has been increased over the last years. platelets contain more than 1100 proteins, include enzymes, enzyme inhibitors, growth factors, immune messengers, and other bioactive compounds which play a role in tissue repair and wound healing. autologous platelet-rich plasma found to promote axon regeneration in studies involving animal models. platelet derived angiogenesis factors are capable of stimulating new capillary growth by inducing migration of endothelial cells. it was suggested that this was the mechanism by which platelet factors influence the process of angiogenesis and revascularization.

Eligibility criteria:
inclusion criteria: * type ii diabetes mellitus * diabetic peripheral neuropathy * six months duration of symptoms, exclusion criteria: * other causes of neuropathy * patient refusal * ulcers or amputations * peripheral vascular diseases * vertebral spine disease * connective tissue disease * platelet dysfunction syndrome * critical thrombocytopenia * local infection * coagulopathy

Keywords: diabetic neuropathies chronic pain
eprime: evaluation of magnetic resonance (mr) imaging to predict neurodevelopmental impairment in preterm infants

Conditions: Cerebral Palsy

Summary: preterm infants face an uncertain future because premature birth often leads to problems with brain development and can cause cerebral palsy. a trial needs to be done to see if magnetic resonance imaging (mri) helps families and professionals by predicting long term problems more accurately, allowing better targeting of care to children with problems and reassuring the parents of normal babies. this programme will provide the evidence-base for the national health system (nhs) policy on the use of magnetic resonance imaging of the brain for preterm infants.

the trial will determine very accurately how well mri predicts long-term problems, and it will assess whether it makes parents more or less anxious about their babies, and whether they seek more or less help in the first couple of years after birth,and see if the total cost to the nhs is increased by using mri. it will also check up if there is a better way to do ultrasound examinations, and do a survey to see how much mri is used in the united kingdon (uk) and whether hospitals think they could provide it. the core of the project is a study of preterm babies who will be referred to a specialist centre to have both ultrasound and mri scans. half the parents will be told the results of the mri and half the parents the ultrasound. the programme will then ask them to fill in questionnaires or be interviewed about their stress levels and the amount of support they seek for their children until they are two years old, when the babies will be examined to see if mri predicted their outcome accurately.

Eligibility criteria:
inclusion criteria: -delivery at less than 33 completed weeks of gestation, estimated from early fetal ultrasonographic measurements as recommended in the national institute of clinical excellence guidelines: antenatal care for the healthy woman exclusion criteria: * prior mr imaging * major congenital malformations * presence of metallic implants
a study of gt267-004 versus vancomycin and gt267-004 versus metronidazole in patients with c. difficile-associated diarrhea

Conditions: Clostridium Enterocolitis; Diarrhea

Summary: approximately 520 patients will be entered into this study taking place throughout australia and europe. this study aims to determine if an investigational drug is safe and effective for treating symptoms of c. difficile-associated diarrhea (cdad) and lowering the risk of repeat episodes of cdad. the investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. all study related care is provided including doctor visits, physical exams, laboratory tests, and study medication. the total length of participation is approximately 6 weeks.


Eligibility criteria:
inclusion criteria: * 18 years of age and above * the presence of cdad at the time of enrollment with no other likely etiology for the diarrhea * less than or equal to 48 hours of treatment with metronidazole, vancomycin or other antibacterial therapy specific for cdad * baseline serum potassium \> 3.0 mmol (meq)/l * patient considered sufficiently stable clinically to likely complete 6 week study period.

Keywords: pseudomembranous colitis clostridium difficile-associated diarrhea c. difficile cdad
the efficacy and safety of escitalopram for depression in multiple sclerosis

Conditions: Depression; Multiple Sclerosis

Summary: emotionally labile, depressed participants with multiple sclerosis treated with escitalopram will have a greater reduction in emotional lability scores and in their psychological distress scores than those who are randomized to receive placebo.

patients with multiple sclerosis who are experiencing mood lability and symptoms of depression will be randomized to receive either escitalopram 10mg/day or placebo tablets for a period of 6 weeks. it is hypothesized that patients receiving medication will experience a greater normalization of their emotional instability and a greater reduction in their depressive symptoms at the end of the six-week trial than those who are not receiving medication.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of multiple sclerosis * having mild to moderate depressive symptoms, with or without emotional lability * experiencing psychological distress exclusion criteria: * meeting dsm-iv diagnostic criteria for major depressive disorder or another axis 1 diagnosis * cognitive impairment * the presence of an unstable medical illness that might preclude completion of the study -

Keywords: depression (mild to moderate) affective symptoms emotional lability multiple sclerosis
assessment of the effect of convalescent plasma therapy in patients with life-threatening covid19 infection

Conditions: COVID19

Summary: * this clinical trial proposal is based on the fda protocol for emergency use of convalescent plasma for treatment of covid-19 cases, and on the who guidelines for use of convalescent plasma in other infectious diseases. * this clinical trial is to be applied in cairo university quarantine hospital. the collection, testing and storage of convalescent plasma will be done inside cuh main blood bank. the concept of this clinical trial is built on the collection of convalescent plasma from individuals who had recovered from documented infection with sars-cov-2, to be used for patients with- or at high risk of progression to- severe/life-threatening clinical conditions due to sars-cov-2 infection. an informed consent is required to join this clinical trial; patients will be transfused with one or two units of abo compatible convalescent plasma. those patients will be followed up and the clinical and laboratory data will be compiled, including adverse events related to the administration of convalescent plasma (cp). other data to be collected retrospectively will include patient demographics, acute care facility resource utilization (total length of stay, days in icu, days intubated, and survival till discharge from an acute care facility).

this study will be done inside cairo university hospitals, it will involve a number of cp donors who were recovered from covid-19 infection and were treated at cairo university isolation hospital. the cp donation process will take place at cuh blood bank ,the number of the donors will be determined at the end of the study as it will vary according to the donation process . the study will also include sixty seven /life threatening covid-19 patients admitted to cairo university isolation hospital.

Eligibility criteria:
inclusion criteria: * must have laboratory confirmed covid-19 and admitted to cairo university isolation hospital. * admitted to acute care facility. * must have severe or immediately life-threatening covid-19: severe disease is defined as: * dyspnea, * respiratory frequency ≥ 30/min, * blood oxygen saturation ≤ 93%, * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \<300, and/or * lung infiltrates \> 50% within 24 to 48 hours (ct finding) life-threatening disease is defined as: * respiratory failure, * septic shock, and/or * multiple organ dysfunction or failure exclusion criteria: * pregnancy * autoimmune disorder * participated in a cp trial in the past 6 months

Keywords: donor recipient convalescent plasma
crizotinib expanded access protocol for ros1 positive nsclc

Conditions: Neoplasms; Carcinoma, Non-Small-Cell Lung

Summary: primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in japan with advanced nsclc harboring a translocation or inversion involving the ros1 oncogene.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of nsclc that is locally advanced or metastatic. * positive for translocation or inversion events involving the ros1 gene as determined by protocol defined test. * ecog performance status 0 to 2. * adequate organ function * patients with brain metastases are eligible if neurologically stable for at least 2 weeks and have no ongoing requirement for corticosteroids. * male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of crizotinib. exclusion criteria: * currently receiving crizotinib or any investigational products. * prior therapy specifically directed against ros1 fusion genes including crizotinib. * carcinomatous meningitis or leptomeningeal disease. * spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function. * ongoing uncontrolled congestive heart failure (chf) and any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack. * ongoing cardiac dysrhythmias of ctcae grade 2, uncontrolled atrial fibrillation of any grade, or qtc more than 480 msec. * history of extensive disseminated/bilateral or known presence of grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis. * pregnant female patients; breastfeeding female patients. * use of drugs or foods including known potent cyp3a4 inhibitors, known potent cyp3a4 inducers and cyp3a4 substrates with narrow therapeutic indices

Keywords: expanded access protocol crizotinib xalkori ros1 japanese a8081064
an evaluation of psychological parameters that may influence the outcome following arthroscopy and arthroplasty for temporomandibular joint surgery

Conditions: Psychological Predictors

Summary: all patients undergoing arthroscopy or arthroplasty for temporomandibular joint dysfunction will complete a psychological questionnaire prior to surgery. the 3 month outcomes including pain and function will be examined using regression analysis to identify psychological variables that may predict outcomes.


Eligibility criteria:
inclusion criteria: * require arthroscopy or arthroplasty exclusion criteria: * age less than 18 yrs * prior surgery * unable to give informed consent